<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01790607</url>
  </required_header>
  <id_info>
    <org_study_id>ONO-2745IVU007</org_study_id>
    <nct_id>NCT01790607</nct_id>
  </id_info>
  <brief_title>An Open-label, Single-dose, Intravenous Administration Study of ONO-2745/CNS 7056 in Subjects With Chronic Hepatic Impairment</brief_title>
  <official_title>An Open-label, Single-dose,Intravenous Administration Study to Compare the Pharmacokinetics and Safety of ONO-2745/CNS 7056 in Subjects With Chronic Hepatic Impairment With Matching Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ono Pharma USA Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ono Pharmaceutical Co. Ltd</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Ono Pharmaceutical Co. Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate and compare the pharmacokinetics and safety of ONO-2745/CNS 7056 in subjects with
      the hepatic impairment and matched healthy subjects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In Part One, 8 subjects with moderate hepatic impairment (Child Pugh Scale B) and 8 matched
      healthy subjects will be enrolled. In Part 2, 8 subjects with mild hepatic impairment
      (Child-Pugh Scale A) and 8 matched healthy subjects will be enrolled. In Part 3, 3 subjects
      with severe hepatic impairment (Child-Pugh Scale C) will be enrolled. Parts 2 and 3 will only
      be initiated if the criteria per protocol is met in Part One. The pharmacokinetics and safety
      profiles will be compared between hepatic impaired subjects and healthy subjects.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2013</start_date>
  <primary_completion_date type="Actual">November 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To study the effect of hepatic impairment on the pharmacokinetics of ONO-2745/CNS 7045 by assessment of drug concentration through blood sample analysis</measure>
    <time_frame>PK: Pre-dose to 4 hours post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>To study the effect of ONO-2745/CNS 7045 on the subjects with hepatic impairment by evaluating the safety parameters per protocol including labs, vitals and adverse events</measure>
    <time_frame>Overall safety: Pre-dose to 7 days post-dose</time_frame>
  </primary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Hepatic Impairment</condition>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Subjects with moderate chronic hepatic impairment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single IV bolus of ONO-2745/CNS 7056 over 1 minute at 0.1 mg/kg body weight</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy subjects matched to moderate hepatic impaired subjects</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single IV bolus of ONO-2745/CNS 7056 over 1 minute at 0.1 mg/kg body weight</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Subjects with mild chronic hepatic impairment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single IV bolus of ONO-2745/CNS 7056 over 1 minute at 0.1 mg/kg body weight</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy subjects matched to mild hepatic impaired subjects</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single IV bolus of NO-2745/CNS 7056 over 1 minute at 0.1 mg/kg body weight</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Subjects with severe chronic hepatic impairment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single IV bolus of ONO-2745/CNS 7056 over 1 minute at 0.1 mg/kg body weight</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ONO-2745 /CNS 7056</intervention_name>
    <arm_group_label>Subjects with moderate chronic hepatic impairment</arm_group_label>
    <arm_group_label>Healthy subjects matched to moderate hepatic impaired subjects</arm_group_label>
    <arm_group_label>Subjects with mild chronic hepatic impairment</arm_group_label>
    <arm_group_label>Healthy subjects matched to mild hepatic impaired subjects</arm_group_label>
    <arm_group_label>Subjects with severe chronic hepatic impairment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males or females between 18 and 65 years of age

          -  Negative test for the selected drugs of abuse at screening

        Hepatic impaired subjects:

          -  Stable hepatic function and medication regimen for at least 28 days prior to check-in

          -  Degree of hepatic impairment will be determined by the Child-Pugh Scale

        Exclusion Criteria:

          -  Clinical manifestation of any disease (except hepatic impaired subjects)

          -  History of significant hypersensitivity, intolerance, or allergy to any drug compound,
             including food, or other substance
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ono Pharma USA, Inc.</last_name>
    <role>Study Director</role>
    <affiliation>Ono Pharmaceutical Co. Ltd</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Anaheim Clinical Site</name>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <zip>92803</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Orlando Clinical Site</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32803</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>South Miami Clinical Site</name>
      <address>
        <city>South Miami</city>
        <state>Florida</state>
        <zip>33034</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 11, 2013</study_first_submitted>
  <study_first_submitted_qc>February 12, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 13, 2013</study_first_posted>
  <last_update_submitted>December 2, 2013</last_update_submitted>
  <last_update_submitted_qc>December 2, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 3, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Adult healthy subjects will be matched with individual subjects by age (± 5 years, gender, and BMI (± 15%)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

